St. Jude Children's Research Hospital
stjude.orgTotal trials
427
Active
145
Phase 3
19
Total enrollment
297,550
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 40 of 141 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Vincristine | — | 20 | |||||
| Methotrexate | — | 18 | |||||
| Cytarabine | — | 24 | |||||
| Dexamethasone | — | 15 | |||||
| Daunorubicin | — | — | — | 7 | |||
| Intrathecal triple therapy | — | — | — | 4 | |||
| Cyclophosphamide | — | — | 51 | ||||
| Etoposide | — | — | 27 | ||||
| Doxorubicin | — | — | — | 13 | |||
| Blinatumomab | — | — | — | 6 | |||
| Dasatinib | — | — | — | 6 | |||
| Mercaptopurine | — | — | — | 8 | |||
| Bortezomib | — | — | — | 6 | |||
| Thioguanine | — | — | — | — | 4 | ||
| Pegaspargase | — | — | — | — | 4 | ||
| Calaspargase Pegol | — | — | — | — | 3 | ||
| Prednisone | — | — | — | 6 | |||
| Ruxolitinib | — | — | — | 4 | |||
| Vorinostat | — | — | — | — | 3 | ||
| Idarubicin | — | — | — | 3 | |||
| Nelarabine | — | — | — | — | 3 | ||
| Clofarabine | — | — | — | 10 | |||
| Erwinase® | — | — | — | — | — | 1 | |
| Asparaginase Erwinia chrysanthemi (recombinant)-rywn | — | — | — | — | — | 1 | |
| COPAD | — | — | — | — | — | 1 | |
| COP, COPD M3, CYM | — | — | — | — | — | 1 | |
| COP, COPADM8, CYVE | — | — | — | — | — | 1 | |
| Fludarabine | — | — | — | — | 26 | ||
| Mesna | — | — | — | — | 19 | ||
| filgrastim | — | — | — | 14 | |||
| G-CSF | — | — | — | — | 12 | ||
| Thiotepa | — | — | — | — | 10 | ||
| Temozolomide | — | — | — | — | 7 | ||
| Melphalan | — | — | — | — | 11 | ||
| carboplatin | — | — | — | — | 8 | ||
| Sorafenib | — | — | — | — | 7 | ||
| Venetoclax | — | — | — | — | 6 | ||
| Anti-thymocyte globulin | — | — | — | — | 6 | ||
| cisplatin | — | — | — | — | 8 | ||
| Bevacizumab | — | — | — | — | 6 |
101 more active programs hidden
Next readouts
- 2015-06
- 2015-08
- 2017-09-27
- 2019-01-11
- 2020-11-16
- 2022-05-10
- 2023-03-17
- 2023-05
- 2023-07-01
- 2023-07-12
Top conditions
- Acute Lymphoblastic Leukemia38
- Sickle Cell Disease34
- Cancer22
- Neuroblastoma19
- Acute Myeloid Leukemia16
- Childhood Cancer16
- Hodgkin Lymphoma16
- Osteosarcoma13
Frequently asked questions about St. Jude Children's Research Hospital
- How many clinical trials does St. Jude Children's Research Hospital have on ClinicalTrials.gov?
- St. Jude Children's Research Hospital is listed as the lead sponsor on 427 clinical trials in ClinicalTrials.gov, 145 of which are currently active (recruiting, enrolling, or ongoing).
- How many of St. Jude Children's Research Hospital's trials are in Phase 3?
- 19 of St. Jude Children's Research Hospital's trials are in Phase 3, spread across 141 active drug programs.
- What therapeutic areas does St. Jude Children's Research Hospital focus on?
- St. Jude Children's Research Hospital's most-studied conditions on ClinicalTrials.gov are Acute Lymphoblastic Leukemia, Sickle Cell Disease, Cancer, Neuroblastoma, Acute Myeloid Leukemia.
- When are St. Jude Children's Research Hospital's next clinical trial readouts?
- St. Jude Children's Research Hospital has 10 upcoming primary-completion readouts tracked here; the soonest is “Phase II Study Incorporating Pegylated Interferon In the Treatment For Children With High-Risk Melanoma”, expected around 2015-06.